Overview

The Over-the-Counter (OTC) Market is a decentralized marketplace where securities are traded directly between parties through a network of broker-dealers, without a centralized exchange such as the NYSE or Nasdaq.

For sale is a U.S.-incorporated publicly traded company operating in the cannabis biotechnology sector, focused on the development and commercialization of cannabinoid-based technologies. The company provides a platform for investors seeking exposure to the regulated cannabis and life sciences markets.

Corporate Status & Reporting

The company is quoted on OTCQB, actively trading, and DTC eligible, ensuring efficient clearing and settlement.

The company is in good standing, current with state and federal tax filings, and classified as a non-shell entity, making it suitable for strategic transactions, capital raises, or operational scaling.

• Fiscal Year-End: December 31
• DTC Eligible: Yes (DWAC enabled)
• Transfer Agent: Pacific Stock Transfer
• Auditor: In place
• Securities Counsel: In place

Capitalization Overview

Preferred Shares Details

Convertible Preferred Shares

• Total: 9,410,000
• Conversion: Convertible into up to ~470,000,000 common shares
• Feature: Provides significant scalability for equity structuring and capital raises

Business Model & Operations

The company focuses on cannabis biotechnology, including:

• Development of cannabinoid-based therapeutics
• Research and commercialization of cannabis-derived technologies
• Potential expansion into regulated cannabis markets and related verticals

Key Points

• Publicly traded OTCQB company (higher tier OTC market)
• Active trading status with multiple market makers
• Established shareholder base (~330 shareholders)
• Fully compliant and in good standing
• No litigation or outstanding legal issues
• Positioned in high-growth cannabis and biotech sectors

Financial Snapshot

• Delivered Assets: ~$300,000
• Delivered Liabilities: ~$650,000

1. No Investment Advice & Confidentiality

This profile is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. The information contained herein has been provided by the Company or other sources deemed reliable but has not been independently verified by the Investment Banker. Prospective buyers should conduct their own ‘Due Diligence’ and consult with legal, financial, and tax advisors before proceeding with any transaction.

2. Forward-Looking Statements (Safe Harbor)

This description contains ‘forward-looking statements’ within the meaning of the Private Securities Litigation Reform Act of 1995. Statements regarding the company’s future growth, market position, and operational scaling involve significant risks and uncertainties. Actual results may differ materially from those projected. The company’s ability to remain on the OTCQB is subject to maintaining compliance with ongoing listing standards.

3. Cannabis Industry Regulatory Risk

The Company operates in the cannabis biotechnology sector. While cannabinoid-based research is legal in many jurisdictions, the cultivation, sale, and distribution of cannabis remain illegal under U.S. Federal Law (Controlled Substances Act). Investors and potential acquirers must be aware of the ‘State vs. Federal’ conflict and the potential impact on banking, taxation (Section 280E), and federal prosecution.

4. Dilution & Preferred Share Conversion Warning

Prospective acquirers should note the significant potential for equity dilution. The 9,410,000 Convertible Preferred Shares are convertible into approximately 470,000,000 Common Shares. Such conversion would significantly dilute the ownership percentage and voting power of existing common shareholders.

5. OTC Market & Liquidity Risk

Securities traded on the OTCQB marketplace are often thinly traded and can be highly volatile. There is no guarantee that a liquid market for these shares will continue or that the company will maintain its OTCQB status. The ‘DTC Eligibility’ and ‘DWAC’ status are subject to change based on the policies of the Depository Trust Company.

6. Non-Shell Representation Disclaimer

While the company is represented as a ‘non-shell’ entity, the final determination of shell status rests with the SEC and FINRA. If the company were deemed a ‘shell’ by regulatory authorities at a later date, significant restrictions on the resale of securities under Rule 144 would apply.